Fortress Biotech Inc (FBIO)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

2 GANSEVOORT STREET NEW YORK, NY 10014

Bio-pharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of inflammatory diseases and cancer.

Data as of 2020-11-22
Market Cap265.179 Million Shares Outstanding93.703 Million Avg 30-day Volume1.198 Million
P/E Ratio-3.3 Dividend Yield EPS-0.85
Price/Sales6.17 Price cash flow ratio Price free cash flow ratio-2.6
Book Value1.04 Price to Tangible Book3.08 Alpha0.0
Short Interest Ratio % Short Interest to Float R-squared0.146322
BETA2.41469 52-week High/Low4.78 / 1.04 Stddev0.266015
View SEC Filings from FBIO instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 76 73 4.11% 22 (1.45%) 22 (1.43%) 0.0%
13F shares: 30.754 Million 22.595 Million 36.11% 17.177 Million 12.724 Million 35.0%
% Ownership 34.9454 27.3969 27.55% 19.5181 15.4274 26.52%
New Positions: 13 28 -53.57% 2 8 -75.0%
Increased Positions 30 21 42.86% 9 5 80.0%
Closed Positions 10 11 -9.09% 2 4 -50.0%
Reduced Positions 14 5 180.0% 5 2 150.0%
Total Calls 0 0
Total Puts 0 0
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding FBIO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding FBIO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HUNTER ROBYN CHIEF FINANCIAL OFFICER

  • Officer
192,169 2020-09-22 1

ROSENWALD LINDSAY A MD PRESIDENT, CEO & CHAIRMAN

  • Officer
  • Director
  • 10% Owner
92,500 2020-08-26 1

HOENLEIN MALCOLM

  • Director
16,667 2020-08-26 2

WEISS MICHAEL S EXECUTIVE VICE CHAIRMAN

  • Officer
  • Director
  • 10% Owner
10,201,811 2020-01-01 1

ROWINSKY ERIC K

  • Director
650,000 2020-01-01 1

LOBELL J JAY

  • Director
1,036,000 2020-01-01 1

KLEIN DOV

  • Director
555,000 2020-01-01 1

HARVEY JIMMIE

  • Director
650,000 2020-01-01 1

LORENZ KEVIN

  • Director
164,582 2020-01-01 1

AVGERINOS GEORGE SVP, BIOLOGICS OPERATIONS

  • Officer
655,170 2018-12-11 0

LU LUCY CHIEF FINANCIAL OFFICER

  • Officer
35,631 2014-12-01 0

BEERMAN NOAH D SEE REMARKS

  • Officer
0 2011-09-26 0

COOPER GLENN L MD SEE GENERAL REMARKS

  • Officer
  • Director
0 2011-09-13 0

SANDAGE BOBBY W PHD PRESIDENT AND CEO

  • Officer
  • Director
0 2011-09-13 0

RITTER DALE SEE GENERAL REMARKS

  • Officer
0 2011-09-13 0

ROGERS MICHAEL W

  • Director
0 2011-09-13 0

BARRETT DAVID JONATHAN

  • Director
0 2011-09-13 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments